⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NTLA News
Intellia Therapeutics, Inc
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
globenewswire.com
CRSP
REGN
NTLA
EDIT
CAT
Global Telehealth Market is Projected to Cross the USD 2 Trillion Mark by 2034, Driven by Digital Healthcare Transformation | DelveInsight
prnewswire.com
TDOC
CSCO
PHG
IBM
MDT
AMWL
GEHC
HPQ
DOX
ISRG
BMBL
ADMA
FLEX
INTC
GOOG
MSFT
AMZN
NVDA
AAPL
TSLA
JNJ
PFE
ABBV
BMY
MRK
XRAY
SYK
BDX
LULU
ROST
ULTA
COST
MCHP
ON
ADI
TXN
QCOM
AMD
SIRI
CMCSA
VZ
T
MU
AMAT
KLAC
LRCX
WDC
SE
BABA
JD
NTES
PDD
IQ
BIDU
FOX
FOXA
NFLX
DIS
CMG
MCD
SBUX
YUM
CVS
EL
ORCL
CRM
NOW
ADBE
INTU
PAYX
ADP
MA
V
AXP
GS
JPM
BAC
WFC
MS
CME
ICE
SCHW
AMGN
GILD
REGN
BIIB
AZN
NVS
SNY
TEVA
CPRT
ALGN
EXPE
BKNG
MAR
HLT
IHG
WYNN
LVS
MGM
EXAS
ACAD
ALKS
VRTX
CRSP
EDIT
NTLA
NBIX
ALNY
BMRN
IDXX
ZBRA
HON
ETR
NEE
DUK
SO
XOM
CVX
SHEL
GOOGL
META
TMUS
AVGO
MRVL
NXPI
INFY
DELL
HPE
LEN
BRK.B
BRK.A
UNH
CI
CNC
ELV
HCA
EBS
TTWO
EA
NTDOY
SONY
GE
BA
GD
LMT
RTX
NOC
CAT
DE
AGCO
CNH
IRTC
HOLX
TNDM
PODD
RMD
MASI
SNOW
DDOG
PANW
FTNT
CRWD
OKTA
SNPS
CDNS
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NTLA
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NTLA
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
prnewswire.com
NAGE
OCGN
NTLA
GERN
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
globenewswire.com
NTLA
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
globenewswire.com
NTLA
Form 8-K
sec.gov
NTLA
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
globenewswire.com
NTLA
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
globenewswire.com
NTLA